Dengue virus evolution and virulence models

Clinical Infectious Diseases

Volumn 44, Issue 11, 2007, Pages 1462-1466

  Rico Hesse, Rebeca ^a  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DENGUE; DENGUE VIRUS; DISEASE CARRIER; EVOLUTION; GENOTYPE; HOST RESISTANCE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; DISEASE MODELS, ANIMAL; EVOLUTION, MOLECULAR; HUMANS; PHYLOGENY; VIRULENCE;

EID: 34249054978     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/517587     Document Type: Article

References (44)

1. World Health Organization. Dengue/dengue hemorrhagic fever. Fact sheet no. 117. 2002. Available at: http://www.who.int/mediacentre/factsheets/ fs117/en/index.html. Accessed 27 December 2006.
2. Gubler DJ. Cities spawn epidemic dengue viruses. Nat Med 2004; 10:129-30.
3. Centers for Disease Control and Prevention. Underdiagnosis of dengue - Laredo, Texas, 1999. MMWR Morb Mortal Wkly Rep 2001; 50:57-9.
4. Ramos M, Abell A, Smith B. Dengue and south Texas: information for clinicians. Tex Med 2006; 102:56-8.
5. Effler PV, Pang L, Kitsutani P, et al. Dengue fever, Hawaii, 2001-2002. Emerg Infect Dis 2005; 11:742-9.
6. Centers for Disease Control and Prevention. Travel-associated dengue - United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:700-2.
7. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421-67.
8. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429-36.
9. Sierra BD, Kouri G, Guzman MG. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 2007; 152:533-42.
10. Gonzalez D, Castro OE, Kouri G, et al. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int J Infect Dis 2005;9:280-5.
11. Marovich M, Grouard-Vogel G, Louder M, et al. Human dendritic cells as targets of dengue virus infection. J Investig Dermatol Symp Proc 2001; 6:219-24.
12. Wu SJ, Grouard-Vogel G, Sun W, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6:816-20.
13. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
14. Murgue B, Roche C, Chungue E, Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000; 60:432-8.
15. Wang WK, Chen HL, Yang CF, et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis 2006; 43:1023-30.
16. Quinlivan ML, Gershon AA, Al Bassam MM, et al. Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts. Proc Natl Acad Sci U S A 2007; 104:208-12.
17. Tanaka Y, Mizokami M. Genetic diversity of hepatitis B virus as an important factor associated with differences in clinical outcomes. J Infect Dis 2007; 195:1-4.
18. Rosen L. The Emperor's New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am J Trop Med Hyg 1977; 26:337-43.
19. Gubler DJ, Reed D, Rosen L, Hitchcock JR Jr. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am J Trop Med Hyg 1978; 27:581-9.
20. Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 1990; 174:479-93.
21. Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997; 230:244-51.
22. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 2003; 9:800-9.
23. Messer WB, Vitarana UT, Sivananthan K, et al. Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. Am J Trop Med Hyg 2002; 66:765-73.
24. Watts DM, Porter KR, Putvatana P, et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 1999; 354:1431-4.
25. Rico-Hesse R. Microevolution and virulence of dengue viruses. Adv Virus Res 2003; 59:315-41.
26. Diaz FJ, Black WCT, Farfan-Ale JA, Lorono-Pino MA, Olson KE, Beaty BJ. Dengue virus circulation and evolution in Mexico: a phylogenetic perspective. Arch Med Res 2006; 37:760-73.
27. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 2004; 189:1411-8.
28. Anderson JR, Rico-Hesse R. Aedes aegypti vectorial capacity is determined by the infecting genotype of dengue virus. Am J Trop Med Hyg 2006; 75:886-92.
29. Cummings DA, Schwartz IB, Billings L, Shaw LB, Burke DS. Dynamic effects of antibody- dependent enhancement on the fitness of viruses. Proc Natl Acad Sci U S A 2005; 102:15259-64.
30. Adams B, Holmes EC, Zhang C, et al. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A 2006; 103:14234-9.
31. Wearing HJ, Rohani P. Ecological and immunological determinants of dengue epidemics. Proc Natl Acad Sci U S A 2006; 103:11802-7.
32. Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006; 80:11418-31.
33. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003; 197:823-9.
34. Brown MG, King CA, Sherren C, Marshall JS, Anderson R. A dominant role for Fcγ RII in antibody-enhanced dengue virus infection of human mast cells and associated CCL5 release. J Leukoc Biol 2006; 80:1242-50.
35. Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcγ RIA (CD64) or Fcγ RIIA (CD32). J Virol 2006; 80:10128-38.
36. Sun P, Celluzzi CM, Marovich M, et al. CD40 ligand enhances dengue viral infection of dendritic cells: a possible mechanism for T cell-mediated immunopathology. J Immunol 2006; 177:6497-503.
37. Bente DA, Rico-Hesse R. Models of dengue virus infection. Drug Discov Today: Animal Models 2006; 3:97-103.
38. Halstead SB, Deen J. The future of dengue vaccines. Lancet 2002; 360:1243-5.
39. Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003; 77:3929-38.
40. Cologna R, Armstrong PM, Rico-Hesse R. Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol 2005; 79:853-9.
41. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J Virol 2005; 79:13797-9.
42. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 2006; 80:10208-17.
43. Ehrenkranz NJ, Ventura AK, Cuadrado RR, Pond WL, Porter JE. Pandemic dengue in Caribbean countries and the southern United States - past, present and potential problems. N Engl J Med 1971; 285:1460-9.
44. Swofford D. PAUP*, phylogenetic analysis using parsimony (*and other methods), ver. 4b10. Sunderland, MA: Sinauer, 2002.